- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07262619
EIK1005-002: Een klinisch onderzoek naar EIK1005, een Werner-helicaseremmer, als monotherapie en in combinatie met pembrolizumab bij deelnemers met gevorderde solide tumoren inclusief tumoren met hoge microsatelliet-instabiliteit (MSI-H)
Een multicenter, multi-part, fase 1/2-studie van EIK1005 als monotherapie en in combinatie met pembrolizumab bij deelnemers met gevorderde solide tumoren, inclusief checkpointremmer-naïeve deelnemers met microsatellietinstabiliteit hoog (MSI-H) of mismatch-repair-deficiënte (dMMR) tumoren
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Ana C Mamede, PharmD
- Telefoonnummer: 347-806-4584
- E-mail: mamedea@eikontx.com
Studie Contact Back-up
- Naam: Krishna Kaza
- E-mail: kazak@eikontx.com
Studie Locaties
-
-
New South Wales
-
Saint Leonards, New South Wales, Australië
- Nog niet aan het werven
- GenesisCare North Shore (Oncology)
-
Waratah, New South Wales, Australië
- Werving
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat, Victoria, Australië
- Werving
- Grampians Health
-
Camperdown, Victoria, Australië
- Werving
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston, Victoria, Australië
- Werving
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston, Victoria, Australië, 3199
- Werving
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Brussels, België, 1020
- Werving
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Berlin, Duitsland, 13125
- Werving
- Helios Klinikum Berlin-Buch
-
Hamburg, Duitsland, 22297
- Werving
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf, Bavaria, Duitsland, 94469
- Werving
- DONAUISAR Klinikum
-
-
-
-
-
Kuopio, Finland, 70210
- Werving
- Kuopio University Hospital
-
-
-
-
Rhone
-
Pierre-Bénite, Rhone, Frankrijk, 69310
- Werving
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Rome, Italië, 00128
- Werving
- Campus Bio-Medico di Rome University
-
-
-
-
-
Wellington, Nieuw-Zeeland
- Werving
- Health New Zealand
-
-
Manawatu
-
Roslyn, Manawatu, Nieuw-Zeeland, 4414
- Werving
- Palmerstone North Hospital
-
-
-
-
-
Oslo, Noorwegen, 0379
- Werving
- Oslo University
-
-
-
-
-
Linz, Oostenrijk, 4020
- Werving
- Ordensklinikum Linz Elisabethinen
-
-
-
-
-
Krakow, Polen, 31-864
- Werving
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz, Polen, 90-338
- Werving
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polen, 70-419
- Werving
- One Day Med
-
-
-
-
-
Lisbon, Portugal, 1649-028
- Werving
- Hospital de Santa Maria
-
Loures, Portugal, 2674-514
- Werving
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto, Portugal, 4200
- Werving
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portugal, 1500-650
- Werving
- Hospital da Luz Lisboa
-
-
-
-
-
Singapore, Singapore, 119074
- Werving
- National University Hospital (NUH)
-
-
Central Region
-
Singapore, Central Region, Singapore, 168583
- Werving
- National Cancer Centre Singapore (NCCS)
-
-
-
-
-
Barcelona, Spanje, 08023
- Werving
- START - Barcelona
-
Logroño, Spanje, 26006
- Werving
- START Rioja - Hospital de San Pedro
-
Madrid, Spanje, 28233
- Werving
- NEXT Madrid HUQSM
-
Zaragoza, Spanje, 50009
- Werving
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma, Balearic Islands, Spanje, 07120
- Werving
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona, Barcelona, Spanje, 8036
- Werving
- Hospital Clinic Barcelona
-
-
-
-
California
-
Los Angeles, California, Verenigde Staten, 90027
- Werving
- California Research Institute (CRI)
-
-
Florida
-
Doral, Florida, Verenigde Staten, 33172
- Werving
- Omnicure Clinical Research
-
Hialeah, Florida, Verenigde Staten, 33013
- Werving
- Bioresearch Partner
-
Plantation, Florida, Verenigde Staten, 33322
- Werving
- Florida Clinical Trials Group
-
Tamarac, Florida, Verenigde Staten, 33321
- Werving
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown, New Jersey, Verenigde Staten, 07960
- Werving
- Morristown Medical Center
-
-
New York
-
Lake Success, New York, Verenigde Staten, 11042
- Werving
- START New York-Long Island
-
New York, New York, Verenigde Staten, 10022
- Werving
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- START Dallas Fort Worth
-
Houston, Texas, Verenigde Staten, 77030
- Werving
- University of Texas MD Anderson Cancer Center
-
-
-
-
-
Seoul, Zuid -Korea, 02841
- Werving
- Korea University Anam Hospital
-
Suwon, Zuid -Korea, 16499
- Werving
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan, Busan, Zuid -Korea, 48108
- Werving
- Inje University-Haeundae Paik Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
Experimenteel: Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
Experimenteel: Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
Tijdsspanne: 21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
Tijdsspanne: From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
Tijdsspanne: Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
Tijdsspanne: Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
Tijdsspanne: Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
Tijdsspanne: Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Tijdsspanne: Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Tijdsspanne: Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Tijdsspanne: Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Tijdsspanne: Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Tijdsspanne: Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Studie directeur: Nilou Mobashery, MD, Eikon Therapeutics, Inc.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Pathologische processen
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Neoplastische processen
- Genitale neoplasmata, vrouwelijk
- Baarmoeder Neoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Neoplasma metastase
- Endometriumneoplasmata
- Turcot -syndroom
- pembrolizumab
Andere studie-ID-nummers
- EIK1005-002
- 2026-525248-13-00 (Ctis)
- KEYNOTE-G56 (Andere identificatie: Merck Sharp & Dohme LLC)
- MK-3475-G56 (Andere identificatie: Merck Sharp & Dohme LLC)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .